Contact
Please use this form to send email to PR contact of this press release:
CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
TO: